BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16336946)

  • 1. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH; Fisher J; Martin BR
    Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR; France CP
    Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
    Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
    Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of brain prostanoid EP3 receptors via arachidonic acid cascade during behavioral suppression induced by Delta8-tetrahydrocannabinol.
    Yamaguchi T; Kubota T; Watanabe S; Yamamoto T
    J Neurochem; 2004 Jan; 88(1):148-54. PubMed ID: 14675158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
    Hutcheson DM; Tzavara ET; Smadja C; Valjent E; Roques BP; Hanoune J; Maldonado R
    Br J Pharmacol; 1998 Dec; 125(7):1567-77. PubMed ID: 9884086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
    Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
    Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
    Tsou K; Patrick SL; Walker JM
    Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
    Yamaguchi T; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2001 Jan; 889(1-2):149-54. PubMed ID: 11166698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
    Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade.
    Anggadiredja K; Nakamichi M; Hiranita T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Neuropsychopharmacology; 2004 Aug; 29(8):1470-8. PubMed ID: 15085091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
    Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
    J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice.
    Darmani NA; Pandya DK
    J Neural Transm (Vienna); 2000; 107(8-9):931-45. PubMed ID: 11041273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism.
    Mitchell MD; Sato TA; Wang A; Keelan JA; Ponnampalam AP; Glass M
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E352-6. PubMed ID: 18042663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
    Cook SA; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol.
    Economidou D; Mattioli L; Ubaldi M; Lourdusamy A; Soverchia L; Hardiman G; Campolongo P; Cuomo V; Ciccocioppo R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):73-85. PubMed ID: 17618662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.